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BACKGROUND: Therapeutic approaches in pediatric populations are based on adult data because there is a lack of
appropriate data for children. Consequently, there are many controversies regarding the proper treatment of
pediatric patients.
OBJECTIVE: The present study was designed to evaluate patients with differentiated thyroid carcinoma diagnosed
before 20 years of age and to determine the factors associated with the response to the initial therapy.
METHODS: Sixty-five patients, treated in two tertiary-care referral centers in Rio de Janeiro between 1980 and 2005
were evaluated. Information about clinical presentation and the response to initial treatment was analyzed and
patients had their risk stratified in Tumor-Node- Metastasis; Age-Metastasis-Extracapsular-Size; distant Metastasis-
Age-Completeness of primary tumor resection-local Invasion-Size and American-Thyroid-Association classification
RESULTS: Patients ages ranged from 4 to 20 years (median 14). The mean follow-up was 12,6 years. Lymph node
metastasis was found in 61.5% and indicated a poor response to initial therapy, with a significant impact on time for
achieving disease free status (p = 0.014 for response to initial therapy and p,0,0001 for disease-free status in follow-
up). Distant metastasis was a predictor of a poor response to initial therapy in these patients (p = 0.014). The risk
stratification systems we analyzed were useful for high-risk patients because they had a high sensitivity and
negative predictive value in determining the response to initial therapy.
CONCLUSIONS: Metastases, both lymph nodal and distant, are important predictors of the persistence of disease
after initial therapy in children and adolescents with differentiated thyroid cancer.
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INTRODUCTION
Differentiated thyroid carcinoma (DTC) is rare in pedia-
tric patients. The incidence of this subtype of carcinoma has
been reported to range from 2.6% to 12.9%.1-6 Papillary
thyroid carcinoma (PTC) is the most common subtype of
DTC in pediatric patients as well as in adult patients
followed by its follicular variant.1,6 Radiation exposure in
infancy has been reported to be associated with the possible
occurrence of PTC.7,8 Advanced tumor manifestations, such
as large or extensive tumor, multicentricity, lymphade-
nopathy, and synchronous lung metastasis at diagnosis,
are more frequent and important risk factors in pedia-
tric patients.1 In addition, young children have a worse
prognosis compared to young adult or adolescent
patients.6,9-16
Treatment of DTC consists of thyroidectomy and an
ablative dosage of iodine-131.17 Radioactive iodine therapy,
after surgery, leads to a significantly improved prognosis,
especially in patients who are at high risk of recurrence or
death by thyroid cancer.18-22 These evidences have been
well documented in adult patients and, due to the lack of
data; have been used as the basis for in younger patients’
treatment. Unfortunately, the first dosage of I-131 is not
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always sufficient to achieve complete ablation of thyroid
remnants.23-25 Zimmerman et al have proved that despite
the more aggressive clinical presentation, the overall
survival rate in patients under 20 years old is better than
in older. Thus, because of the clinical trade-off between
aggressive manifestation and better outcomes, controversy
still remains concerning the appropriate treatment for
pediatric DTC patients.5
Regarding thyroid remnant ablation, little is known about
the prognostic significance of achieving good response to
initial therapy with the first dosage of I-131 in patients with
differentiated thyroid cancer. Verburg et al have shown that
adult patients with good response to initial therapy had a
better prognosis than those with poor response: disease-free
survival was 87% versus 49% after 10 years; additionally,
thyroid-cancer related survival was 93% versus 78%.26
The aim of this study is to evaluate patients with DTC
who were diagnosed under 20 years old and analyze the
factors that may influence the success of initial therapy.
PATIENT AND METHODS
This was a retrospective study of a cohort of patients
diagnosed with DTC under 20 years old. The data was
gathered in the files of the Universidade Federal do Rio de
Janeiro and at the. Instituto Nacional do Cancer. Between
January of 1980 and December of 2005, 73 pediatric patients
(# 20 years) with DTC were initially treated in both
institutions. Among the 73 consecutive patients, 8 were
submitted to partial thyroidectomy and, so excluded from
the analysis. The remaining 65 patients (17 males and 48
females) underwent total thyroidectomy and radioactive
iodine initial therapy with I-131 within 2-6 months after
surgery. Therapeutic neck dissection was performed only if
the patients had enlarged and suspicious lymphadenopathy
or biopsy proven lymph node metastases. No prophylactic
neck dissection was performed. Pre-operative neck ultra-
sounds were not routinely performed in all patients at the
time they were included in the study. The age ranged from 4
to 20 years old (median 14) and the mean follow-up was 12,6
years (ranging from 5-32 years). Patients with positive
thyroglobulin antibodies, medullary thyroid carcinoma
or anaplastic thyroid carcinoma were excluded. Serum
thyroglobulin was quantified by immunometric assay
(ImmuliteH) with analytical sensitivity of 0.2 ng/ml, func-
tional sensitivity of 0.9 ng/ml and interassay variation up to
8.8%.
Evaluation of outcomes
Clinicopathological features, treatments, and outcomes,
such as age, gender, histology, specific variant, tumor size,
extrathyroidal extension, tumor stage, presence of patholo-
gical node metastases, extension of thyroid resection and
node dissection, surgical complications, and data from
radioactive iodine therapy were obtained. These factors
were compared among patients, independently from their
responses to initial therapy. The patients were stratified in
four systems of risk: TNM (Tumor, Node, Metastasis),
employed by the American Joint Committee on Cancer
(AJCC)/ International Union Against Cancer (UICC) (27),
which is widely used for all types of cancers, AMES (Age,
Metastasis, Extracapsular tumor and Size) 28 MACIS (distant
metastasis, age, completeness of primary tumor resection,
local invasion, tumor size),developed by the Mayo Clinic 29
and the recently published ATA risk classification for
DTC30. These systems were designed for adults and
consider only two different populations, older than 45 years
old and younger than 45 years old, which leaves children,
adolescents and young adults in the same group.
This study was approved by the Ethical boards of both
institutions involved. Informed consent was obtained from
patients and/or their parents.
Statistical Analysis
The results are expressed as the median and the range of
variation. Frequencies were compared with the Fisher’s
exact probability test. We calculated relative risks [RR; 95%
confidence interval (CI)] to evaluate the effects of each factor
on the response to initial therapy. The performance of the
different staging systems was measured by their sensitivity,
specificity, positive and negative predictive value and their
confidence interval at 95% (CI) considering as ‘‘positive
test’’ the lower stage of each classification and for ‘‘negative
test’’ the combination of stages two and three for ATA and
MACIS classification. Differences were considered statisti-
cally significant when p-values were less than 0.05.
Statistical analyses were performed with Stata 9.0 (STATA
CORPORATION, 2005).
Follow-up and definition of Good response to
initial therapy
Patient follow-up was performed every 6-12 months after
initial treatment with surgery and radioactive iodine
therapy. The success of initial therapy was defined as a
negative whole body scan associated with undetectable
thyroglobulin levels in hypothyroid patients and negative
thyroglobulin antibodies after 6 to 12 months and no
evidence of structural disease in cross-sectional images
when performed. When the patient had a partial response at
the beginning such as shrinkage in structural disease and
decrease in thyroglobulin levels and still had iodine avid
tumor they were retreated with I131 with at least 6 months
interval between the treatments.
RESULTS
There were 45 patients (69.2%) with classic papillary
thyroid cancer, 16 with follicular variant types (24.7%), 2
with follicular thyroid carcinoma (2.7%) and 2 with Hurthle
cell carcinoma (2.7%). Extrathyroidal extension was found
in 39.5%, metastatic lymphadenopathy in 61.5%, multi-
centricity in 26.2% and distant metastasis in 29.2%, all of
them in the lungs.
Overall, permanent surgical complications such as hypo-
parathyroidism were observed in 32.4% of the patients.
There was no patient with damage to laryngeal nerves,
neither recurrent laryngeal nerve nor superior laryngeal
lesions. All the patients underwent total thyroidectomy,
50% lateral neck dissection as their first surgery and at least
one initial therapeutic dose of radioactive iodine (I-131),
which. The (mean activity of I-131 administered was
132 mCi (488.4 MBq) ranging from 50 to 200 mCi. The post
therapy scan showed iodine uptake outside the thyroid bed
in 29.3% of the patients while 70.7% had uptake only in the
thyroid bed. However, the post therapy scan uptake pattern
was not statistically significant in predicting the success of
the initial therapy in this specific population. (Table 1)
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Regarding the staging, 70.77% (46 patients) were TNM
stage I and 29.23% stage II. The same proportion was found
for the AMES staging system for low and high risk. For the
MACIS staging system, 72.31% had less than 6 points,
considered low risk, 10.77% had between 7 and 7.99 points,
so called intermediate risk and 16.92% had above 8 points,
high risk – there was no patient between 6 and 6.99 points.
For the ATA classification, 21.54% were considered low risk,
52.31% intermediate, and 26.15% high risk.
The factors that negatively influenced the success of the
initial therapy in this pediatric cohort were the presence of
lymph node metastasis and distant metastasis. Neither age
nor gender nor tumor size influenced in this outcome as
shown in table 1.
All of the staging systems analyzed was able to predict a
lower success of initial therapy among the high risk patients
(high negative predictive value). The ATA classification was
slightly superior to the others (table 2). However, all of the
systems had a very low specificity and positive predictive
value (table 3).
Patients classified as poor response to initial therapy
underwent subsequent doses of radioactive iodine
therapy.Total activity of radiopharmaceutical administered
averaged 333 mCi (1232.1 MBq) ranging from 100 to
1150 mCi total activity. Transient leucopenia was observed
in 2 patients, transient anemia in one with recovery 1 month
after the last dose. After multiple doses of radioactive
iodine, 50,8% achieved a disease free status at the end of
the observation period (figure 1). Two patients had lymph
node recurrence and two recurred in the thyroid bed and
underwent further surgery. Only two patients developed
new distant metastases, in both cases, lung metastases.
In this same analysis, the risk-stratification systems failed
to predict response to therapy, except for the ATA
classification (p = 0.02) (figure 2). Between the patients that
had no evidence of disease during some point in the follow
up, patients that had lymph node metastases at the diag-
nosis took a longer time to be without evidence of disease
(p,0.001) (figure 2). Sixty percent of the patients with
distant metastases at diagnosis did not achieve the disease-
free status at the end of follow up, with the 40% that did, the
analysis had no statistical significance. Only 6 patients had
progressive disease and it was not possible to perform
statistical analysis due to the small number. The overall
survival was 100%.
DISCUSSION
Data regarding the management of DTC in pediatric
patients is scarce in the literature. This present study had
the aim to determine prognostic factors that may predict
which children with DTC will become free of disease after
initial therapy with radioactive iodine. The findings of the
study demonstrated that a large number of children are not
free of disease after initial therapy (even when considered
‘‘low risk’’ by conventional staging systems) and that
clinical factor such as extent of initial disease presentation,
especially lymph node metastasis, seemed to be important
to predict outcomes after initial therapy in this population.
In addition, most of the patients either are free of disease in
some point in the follow up or they had persistent stable
disease in this present study. The overall survival was very
good as previously shown in other studies.
Pediatric series had already shown that thyroid cancer is
the most common endocrine malignancy in children. The
principal thyroid malignancies in children have the same
histology as those afflicting adults, including papillary,
Table 1 - Initial presentation and good response to initial
therapy with I-131-Therapy.
N % RR (95% CI )* P-value
Age .10 56 1 0,328
,10 9 0,38 (0,05-2,5)
Gender F 48 1 0,188
M 16 0,4 (0,1-1,5)
Size .2cm 57 1 0,372
,2cm 8 0,63(0,23-1,73)
Lymph node
metastasis
Y 40 1 0,014
N 25 0,34 (0,14-0,8)
Multicentricity Y 17 1 0,719
N 48 1,17 (0,48-2,84)
Distant Metastasis Y 19 1 0,014
N 46 0,15 (0,02-0,96)
Post therapy scan
uptake
TB 45 1 0,353
OTB 20 0,52 (0,17-1,60)
*RR – risk relative; 95% CI – 95 confidence interval, Y- yes (present at
diagnosis), N- No (absent at diagnosis; TB- Thyroid bed; OTB-outside
thyroid bed
Table 2 - Staging systems and prediction of good
response to initial therapy.
I II III IV P-value
TNM NED 16 1 0,014
Persistent 30 18
MACIS NED 16 0 1 3 0,019
Persistent 31 7 7
AMES NED 16 1 0,014
Persistent 30 18
ATA NED 9 7 1 0,001
Persistent 5 27 16
NED=no evidence of disease; Persistent = persistent disease; MACIS
(I =,6 points; II = 6-6.99; III- 7-7.99 and IV- .8); AMES ( I- low risk; II-high
risk); ATA (I-Low risk; II- Intermediate Risk and III- High risk)
Table 3 - Accuracy and the staging system on predicting good response to initial therapy.
Measurements TNM%(CI 95%) MACIS%(CI 95%) AMES% (CI 95%) ATA% (CI 95%)
Sensitivity 94.12 (71.31- 99.85) 94.12 (71.31- 99.85) 94.12 (71.31- 99.85) 94.12 (71.31- 99.85)
Specificity 37.5 (23.95- 52.65) 35.42 (22.16- 50.54) 37.5 (23.95- 52.65) 33.33 (20.40-48.41)
Positive predictive value 34.78 (21.35- 50.25) 34.04 (20.86- 49.31) 34.78 (21.35-50.25) 33.33 (20.40- 48.41)
Negative predictive value 94.74 (73.97- 99.87) 94.44 (72.71- 99.86) 94.74 (73.97- 99.87) 94.12 (71.31- 99.85)
95% CI – 95 confidence interval
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follicular, and medullary thyroid cancer. However, children
tend to present a more advanced disease, with a greater
frequency of lymph-node metastasis and distant metastasis
at the time of diagnosis and high rates of recurrence during
the first decade of life. In this study, there was a higher
incidence in females (3 to 1) and it increases according to the
age, with a high incidence of lymph node metastasis,
(61.54%) and also distant metastasis (26.15%) all of them in
the lung. The results from a large cohort of the SEER
(Surveillance, Epidemiology and End Results) also confirm
these data. In the study by Hogan et al., female patients
outnumbered male patients by more than 4 to 1 and 95% of
the patients were more than 10 years old. Distant metastases
were found in 133 (7.6%) of the patients at the time of
diagnosis and were most commonly found in the lung –
rarely in the bone or liver. Regional lymph-node metastases
were found in 814 patients (46%), and disease confined to
the thyroid gland was found in 741 (42%).31 The most
Figure 1 - Kaplan-Meier curve of disease-free state in young papillary thyroid carcinoma patients after the first treatment.
Figure 2 - Kaplan-Meier curve of disease-free state in young papillary thyroid carcinoma patients after the first treatment according to:
(a) ATA staging system classification (1= low risk; 2 = intermediate risk; 3=high risk); (b) Lymph node metastases at diagnosis.
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common tumor histology, in the present study, was also
papillary thyroid cancer followed by its follicular variant, in
line with previous studies.31
The initial therapeutic approach for children and adoles-
cents with DTC is still a controversial issue. Many
authors32,33 advocate a routine of intensive approach
because of the more advanced disease at diagnosis,
propensity for recurrence, and greater radioiodine respon-
siveness in children. This intensive approach consists of
total thyroidectomy followed by radioiodine administration.
Although the prognostic significance of achieving good
response to initial therapy with the first dosage of I-131 in
patients with differentiated thyroid cancer is still uncertain
even in adults, Verburg et al, in a study with 180 adult
patients with DTC with good response to initial therapy,
leads to a better prognosis 26. The most important variables
that influenced the good response to initial therapy in this
present study were the absence of lymph node metastasis
and absence of distant metastasis. Surprisingly, however,
age at the time of initial therapy had no statistically
significant influence on the outcome of the first dosage of
I-131 in our study population. Normally, age is considered
to be one of the most important prognostic factors in thyroid
cancer.30 The role of lymphadenopathy in low risk pediatric
patients has been recently studied by Wada N et al by
analyzing 57 consecutive TNM stage I patients (with 15
years or less) with DTC. The study showed that clinical
lymphadenopathy (p = 0.006) was a risk factors for disease
free survival in stage I pediatric patients.34
Regarding the staging systems analyzed, all of them were
able to identify high risk with a good correlation with poor
response to initial therapy, expressed as high negative
predictive value. Nonetheless, none of the examined staging
classifications was accurate to identify the low risk patients.
Likewise other authors showed, the current used staging
systems, especially TNM, was not accurate to determinate
disease free survival in low risk patients.34 In fact, most of
these systems were designed to predict mortality, which
might explain slight superiority of the ATA classification
(p = 0,014 for TNM vs p = 0,001for ATA) that was designed
to predict recurrence and takes into account information
about histology and response to initial treatment such as
uptake outside the thyroid bed on the first post-treatment
whole-body radioactive iodine scan and thyroglobulin
levels.30
The role of radioactive iodine therapy in children and
adolescents is still unclear. Chow et al,32 in a univariate
analysis showed that adjuvant therapy with I-131 decreased
the recurrence rate from 42% to 6,3%, however they did not
risk-stratified the patients. On the other hand, the Mayo
Clinic studies did not show a major impact in the overall
survival and in the recurrence rates.5,35 In this study, after
multiple treatments with radioactive iodine, the disease-free
survival status increased from 26.5% to 50.8% but as most of
the patients showed uptake in the thyroid bed, this might be
due to the ablation of normal thyroid tissue and there is not
enough data to analyze its impact on the recurrence rates
and overall survival.
In conclusion, the present study, which analyzed a
Brazilian cohort of 65 patients diagnosed with DTC under
20 years of age, suggests that young patients have a more
aggressive clinical presentation with more frequent lymph
node and distant metastasis comparing to what is usually
seen in adults. Those, in fact, seem to be the most important
prognostic factors for the good response to initial therapy in
these patients. Unfortunately, most of the risk stratification
systems do not give enough emphasis to the presence of
lymph node metastasis in this population which might
decrease the ability to identify ‘‘real low-risk patients’. Since
DTC has a very long overall survival, this fact might leads to
undertreatment with a less aggressive initial therapy.
Certainly, further studies are needed to determinate the
prognostic significance of a good response to initial therapy
in pediatric population and to propose other ways of
stratifying young patients based on disease free survival
and recurrence rate instead of on cause specific death,
which will more accurate identify low risk patients.
REFERENCES
1. Danese D, Gardini A, Farsetti A, Sciacchitano S, Andreoli M, Pontecorvi
A. Thyroid carcinoma in children and adolescents. Eur J Pediatr.
1997;156:190-4, doi: 10.1007/s004310050580.
2. Dottorini ME, Vignati A, Mazzucchelli L, Lomuscio G, Colombo L.
Differentiated thyroid carcinoma in children and adolescents: a 37-year
experience in 85 patients. J Nucl Med. 1997;38:669-75.
3. Lee YM, Lo CY, Lam KY, Wan KY, Tam PK. Well-differentiated thyroid
carcinoma in Hong Kong Chinese patients under 21 years of age: a 35-
year experience. J Am Coll Surg. 2002;194:711-6, doi: 10.1016/S1072-
7515(02)01139-0.
4. Popovtzer A, Shpitzer T, Bahar G, Feinmesser R, Segal K. Thyroid cancer
in children: management and outcome experience of a referral center.
Otolaryngol Head Neck Surg. 2006;135:581-4, doi: 10.1016/j.otohns.2006.
04.004.
5. Zimmerman D, Hay ID, Gough IR, Goellner JR, Ryan JJ, Grant CS,
McConahey WM. Papillary thyroid carcinoma in children and adults:
long-term follow-up of 1039 patients conservatively treated at one
institution during three decades. Surgery. 1988; 104:1157-66.
6. Bal CS, Padhy AK, Kumar A. Clinical features of differentiated thyroid
carcinoma in children and adolescents from a sub-Himalayan iodine-
deficient endemic zone. Nucl Med Commun. 2001;22:881-7, doi: 10.1097/
00006231-200108000-00006.
7. Spinelli C, Bertocchini A, Antonelli A, Miccoli P. Surgical therapy of the
thyroid papillary carcinoma in children: experience with 56 patients ,
or = 16 years old. J Pediatr Surg. 2004; 39:1500-5, doi: 10.1016/j.jpedsurg.
2004.06.016.
8. Farahati J, Bucsky P, Parlowsky T, Ma¨der U, Reiners C. Characteristics of
differentiated thyroid carcinoma in children and adolescents with
respect to age, gender, and histology. Cancer, 1997;80:2156-2, doi: 10.
1002/(SICI)1097-0142(19971201)80:11,2156::AID-CNCR16.3.0.CO;2-Y.
9. Borson-Chazot F, Causeret S, Lifante JC, Augros M, Berger N, Peix JL.
Predictive factors for recurrence from a series of 74 children and
adolescents with differentiated thyroid cancer. World J Surg.
2004;28:1088-92, doi: 10.1007/s00268-004-7630-y.
10. Welch Dinauer CA, Tuttle RM, Robie DK, McClellan DR, Svec RL, Adair
C, et al. Clinical features associated with metastasis and recurrence of
differentiated thyroid cancer in children, adolescents and young adults.
Clin Endocrinol (Oxf). 1998; 49:619-28, doi: 10.1046/j.1365-2265.1998.
00584.x.
11. Palmer BA, Zarroug AE, Poley RN, Kollars JP, Moir CR. Papillary
thyroid carcinoma in children: risk factors and complications of disease
recurrence. J Pediatr Surg. 2005; 40:1284-8, doi: 10.1016/j.jpedsurg.2005.
05.012.
12. Chaukar DA, Rangarajan V, Nair N, Dcruz AK, Nadkarni MS, Pai PS,
et al. Pediatric thyroid cancer. J Surg Oncol. 2005; 92:130-3, doi: 10.1002/
jso.20339.
13. Jarzab B, Handkiewicz Junak D, Włoch J, Kalemba B, Roskosz J, et al.
Multivariate analysis of prognostic factors for differentiated thyroid
carcinoma in children. Eur J Nucl Med. 2000;27:833-41, doi: 10.1007/
s002590000271.
14. Vassilopoulou-Sellin R, Klein MJ, Smith TH, Samaan NA, Frankenthaler
RA, Goepfert H, et al. Pulmonary metastases in children and young
adults with differentiated thyroid cancer. Cancer. 1993;71:1348-52, doi:
10.1002/1097-0142(19930215)71:4,1348::AID-CNCR2820710429.3.0.
CO;2-3.
15. Newman KD, Black T, Heller G, Azizkhan RG, Holcomb GW 3rd, Sklar
C, et al. Differentiated thyroid cancer: determinants of disease progres-
sion in patients ,21 years of age at diagnosis: a report from the Surgical
Discipline Committee of the Children’s Cancer Group. Ann Surg.
1998;227:533-41, doi: 10.1097/00000658-199804000-00014.
16. Massimino M, Gasparini M, Ballerini E, Del Bo R. Primary thyroid
carcinoma in children: a retrospective study of 20 patients. Med Pediatr
Oncol.1995;24:13-7, doi: 10.1002/mpo.2950240104.
CLINICS 2011;66(2):281-286 Prognostic factors in juvenille thyroid cancer
Vaisman F et al.
285
17. Schlumberger MJ. Papillary and follicular thyroid carcinoma. New
Engl J Med. 1998;338:297–306, doi: 10.1056/NEJM199801293380506.
18. Mazzaferri EL & Jhiang SM. Long-term impact of initial surgical and
medical therapy on papillary and follicular thyroid cancer. Am J Med.
1994;97:418–28, doi: 10.1016/0002-9343(94)90321-2.
19. Simpson WJ, McKinney SE, Carruthers JS, Gospodarowicz MK,Sutcliffe
SB & Panzarella T. Papillary and follicular thyroid cancer. Prognostic
factors in 1,578 patients. Am J Med. 1987;83 479–88, doi: 10.1016/0002-
9343(87)90758-3.
20. DeGroot LJ, Kaplan EL, McCormick M, Straus FH: Natural history,
treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol
Metab. 1990;71 414–24, doi: 10.1210/jcem-71-2-414.
21. Samaan NA, Schultz PN, Hickey RC, Goepfert H, Haynie TP,Johnston
DA, et al. The results of various modalities of treatment of well
differentiated thyroid carcinomas: a retrospective review of 1599
patients. J Clin Endocrinol Metab. 1992;75:714–20, doi: 10.1210/jc.75.3.
714.
22. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G &
Gerstein HC. Clinical review 170: a systematic review and metaanalysis
of the effectiveness of radioactive iodine remnant initial therapy for well-
differentiated thyroid cancer. J Clin Endocrinol Metab. 2004;89:3668–76,
doi: 10.1210/jc.2003-031167.
23. Doi SA, Woodhouse NJ. Initial therapy of the thyroid remnant and 131I
dose in differentiated thyroid cancer. Clin Endocrinol (Oxf). 2000;52:765–
73, doi: 10.1046/j.1365-2265.2000.01014.x.
24. de Klerk JM, de Keizer B, Zelissen PM, Lips CM, Koppeschaar HP. Fixed
dosage of 131I for remnant initial therapy in patients with differentiated
thyroid carcinoma without pre-ablative diagnostic 131I scintigraphy.
Nucl Med Commun. 2000; 21:529–32, doi: 10.1097/00006231-200006000-
00005.
25. Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M. Is
diagnostic iodine-131 scanning useful after total thyroid initial therapy
for differentiated thyroid cancer? J Clin Endocrinol Metab. 2000;85:175–8,
doi: 10.1210/jc.85.1.175.
26. Verburg F A, Keizer B, Lips CJM, Zelissen PMJ and de Klerk JMH
Prognostic significance of good response to initial therapy with radio-
iodine of differentiated thyroid cancer patients. Eur J Endocrinol.
2005;152:33–7, doi: 10.1530/eje.1.01819.
27. International Union Against Cancer (UICC) 2009: ‘‘TNM classification of
malignant tumors.’’7th ed. New York: Wiley
28. Cady B. Presidential address: beyond risk groups–a new look at differ-
entiated thyroid cancer. Surgery. 1998;124 947–57, doi: 10.1016/S0039-
6060(98)70034-0.
29. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting
outcome in papillary thyroid carcinoma: development of a reliable
prognostic scoring system in a cohort of 1779 patients surgically treated
at one institution during 1940 through 1989. Surgery. 1993;114:1050–7.
30. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al.
Revised American Thyroid Association Management Guidelines for
Patients with Thyroid Nodules and Differentiated Thyroid Cancer.
Thyroid. 2009;19:1167-214, doi: 10.1089/thy.2009.0110.
31. Hogan AR, Zhuge Y, Perez EA, Koniaris LG, Lew JI, Sola JE. Pediatric
thyroid carcinoma: incidence and outcomes in 1753 patients. J Surg Res.
2009;156:167-72, doi: 10.1016/j.jss.2009.03.098.
32. Chow SM, Law SC, Mendenhall WM, Au SK, Yau S, Mang O, et al.
Differentiated thyroid carcinoma in childhood and adolescence-clinical
course and role of radioiodine. Ped Blood Cancer. 2004a42:176–83, doi:
10.1002/pbc.10410.
33. Jarzab B, Handkiewicz-Junak D, J Włoch J. Juvenile differentiated
thyroid carcinoma and the role of radioiodine in its treatment: a
qualitative review Endocrine-Related Cancer 2005;12:773–803.
34. Wada N, Sugino K, Mimura T, Nagahama M, Kitagawa W, Shibuya H,
Ohkuwa K et al. Pediatric differentiated thyroid carcinoma in stage I:
risk factor analysis for disease free survival BMC Cancer. 2009;9:306-8.
35. Hay ID, Gonzalez-Lousada T, Reunalda MS, Honetschalger JA, Richards
ML, Thompson GB. Long-Term Outcome in 215 Children and
Adolescents with Papillary Thyroid cancer Treated During 1940 though
2008. World J Surg. 2010;34:1192-202, doi: 10.1007/s00268-009-0364-0.
Prognostic factors in juvenille thyroid cancer
Vaisman F et al.
CLINICS 2011;66(2):281-286
286
